2003
DOI: 10.1016/s1521-6616(03)00036-6
|View full text |Cite
|
Sign up to set email alerts
|

Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

9
65
0

Year Published

2006
2006
2020
2020

Publication Types

Select...
5
2
1

Relationship

1
7

Authors

Journals

citations
Cited by 86 publications
(74 citation statements)
references
References 25 publications
9
65
0
Order By: Relevance
“…From these latter studies, high titer Ab responses to NeuGc-containing gangliosides were measured in the sera of cancer patients. A fraction of non-suppressible anti-NeuGc-containing ganglioside Abs was demonstrated through adsorption of these sera with 1E10 mAb, suggesting that 1E10 Id vaccination might enhance antitumor natural immune response (20,26). Furthermore, NeuGcGM3-specific IFN-␥-secreting cells were measured by ELISPOT from PBMC of 1E10-vaccinated breast cancer patients (27).…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…From these latter studies, high titer Ab responses to NeuGc-containing gangliosides were measured in the sera of cancer patients. A fraction of non-suppressible anti-NeuGc-containing ganglioside Abs was demonstrated through adsorption of these sera with 1E10 mAb, suggesting that 1E10 Id vaccination might enhance antitumor natural immune response (20,26). Furthermore, NeuGcGM3-specific IFN-␥-secreting cells were measured by ELISPOT from PBMC of 1E10-vaccinated breast cancer patients (27).…”
mentioning
confidence: 99%
“…This Ab2, named 1E10 (17), was generated from the immunization of BALB/c mice with P3, an idiotypic Ab (Ab1) that recognizes NeuGc-containing gangliosides, sulfated glycolipids, and Ags present in different human tumors including those from the lung, and which contains a regulatory Id according to Bona's concept (18 -24). Preparations containing 1E10 mAb were able to induce antitumor effects against lung metastases in murine models, and phase I clinical trials have proven the safety and immunogenicity of 1E10 Id vaccination in melanoma and breast cancer patients (20,25,26). From these latter studies, high titer Ab responses to NeuGc-containing gangliosides were measured in the sera of cancer patients.…”
mentioning
confidence: 99%
“…[58][59][60][61]63 A positive correlation between the development of such antibodies and patient survival was found. 63 Despite the lack of direct cytotoxicity by P3 mAb, 66 the antibodies generated by the anti-idiotypic vaccine were able to directly kill GM3(Neu5Gc)-expressing cells.…”
Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning
confidence: 78%
“…GM3(Neu5Gc) is a ganglioside whose expression has been detected in some human tumors, including breast and melanoma. 53,55,56 Several therapeutic strategies have been developed against this target, 14 e.g., vaccines (ganglioside-based 57 and antiidiotypic [58][59][60][61][62][63] ) and mAbs. 55 14F7 mAb is specific for this ganglioside and unable to bind its N-acetylated (Neu5Ac) counterpart.…”
Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning
confidence: 99%
“…: GD2 in neuroblastomas, GD3 in melanomas, GM3 and GD3 on breast carcinomas), normal cells show negative or faint reaction with relevant anti ganglioside antibodies. Gangliosides may serve as useful target antigen for antibody mediated immunotherapy (11,12). As it is diffi-cult to get human anti-GD3 antibodies because of their little immunogenicity, our novel way to develop antibody fragments with this specificity on breast carcinomas seems to be of great interest.…”
mentioning
confidence: 99%